Convalescent Plasma Treatment in Severe 2009 H1N1 Infection

The University of Hong Kong80 enrolled

Overview

Treatment of severe 2009 H1N1 infection with convalescent plasma will reduce mortality.

Patients presented with severe 2009 H1N1 infection responded poorly to antiviral agents. Meta-analysis of reports from 1918 H1N1 pandemic suggested that convalescent plasma might be an effective treatment option for patients with severe 2009 H1N1 infection.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Influenza A

Interventions

H1N1 convalescent plasma and oseltamivirDRUG

Oseltamivir 75mg bid orally during ICU hospitalization + 500mL convalescent plasma containing \>= 1:160 of neutralizing antibody to Pandemic influenza A H1N1

Oral Oseltamivir aloneDRUG

Oral Oseltamivir 75mg bid during ICU hospitalization

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * adult patients ≥ 18 years old with written informed consent given by patient or next-of-kin * laboratory confirmatory diagnosis of 2009 H1N1 infection by positive RT-PCR from respiratory specimens * required intensive care within 7 days of onset of symptoms Exclusion Criteria: * age 18 years old or below * known hypersensitivity to immune globulin * known IgA deficiency

Locations (1)

The University of Hong Kong, Queen Mary Hospital

Hong Kong SAR, China